Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition

Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020......»»

Category: topSource: marketwatchDec 3rd, 2019

$4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Category: topSource: bizjournalsSep 3rd, 2019

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

Category: topSource: reutersDec 23rd, 2019

Roche enters $1.15 billion licensing deal for Sarepta gene therapy

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States......»»

Category: topSource: reutersDec 23rd, 2019

Roche to complete $4.3 billion Spark deal as regulators give all clear

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment......»»

Category: topSource: reutersDec 17th, 2019

U.S. approves Roche"s $4.3 billion purchase of Spark Therapeutics

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A......»»

Category: topSource: reutersDec 16th, 2019

Astellas bets $3 billion in gene therapy deal

Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that it plans to acquire Audentes.....»»

Category: topSource: marketwatchDec 3rd, 2019

FTC staff recommends approval of Roche deal for Spark: report

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»

Category: topSource: reutersOct 24th, 2019

Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

Roche has extended, yet again, its tender offer to Spark Therapeutics in connection with the proposed $4.3 billion purchase of the Philadelphia gene therapy pioneer. For those keeping track, this is the fifth time the companies announced a new deadl.....»»

Category: topSource: bizjournalsJul 31st, 2019

Roche, Spark push back takeover deadline in $4.3 billion deal

Swiss drugmaker Roche has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction and expects it to close this year......»»

Category: topSource: reutersJul 8th, 2019

Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion......»»

Category: topSource: marketwatchJun 17th, 2019

$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Category: topSource: bizjournalsJun 10th, 2019

Roche"s $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition......»»

Category: topSource: reutersJun 10th, 2019

Roche says $4.3 billion Spark offer still on track for June completion

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it......»»

Category: topSource: reutersApr 3rd, 2019

Roche bids $4.8B for Spark and its gene therapy

Roche Holding AG will buy Spark Therapeutics Inc. for $4.8 billion, a deal that will give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes......»»

Category: topSource: moneycentralFeb 25th, 2019

Roche bets $4.3 billionon Spark in gene therapy move

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

Category: topSource: moneycentralFeb 25th, 2019

The Petri Dish: A $2.1B acquisition and gene therapy IPOs

In the last week, a gene therapy company announced plans for a $100M IPO, a Waltham biopharma was acquired for upwards of $2.1 billion and announced collaborations......»»

Category: topSource: bizjournalsJun 12th, 2020

Investors expect any T-Mobile/Sprint deal price haircut to be small

T-Mobile US Inc may be limited in its ability to trim the price of its $40 billion acquisition of Sprint Corp after it overcame regulatory obstacles to completing the deal, investors and analysts said on Tuesday......»»

Category: topSource: reutersFeb 11th, 2020

Gene therapy invented at Nationwide Children"s lands $1.1B commercialization deal for Boston biotech

A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus office will play a big role in getting the treatment to the market. Sarepta Th.....»»

Category: topSource: bizjournalsDec 24th, 2019

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy......»»

Category: blogSource: 247wallstDec 23rd, 2019

Sarepta"s "transformative" Roche deal validates DMD gene therapy, says Baird

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 23rd, 2019